Physician profile
Melissa Blandford
NPI 1255767158
$5,949.19
in general payments reported to CMS, 2019-2025
55 companies · $2,076 in 2025
The $2,076 reported for 2025 was more than what 80% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $867 · 2023: $1,214 · 2024: $1,463 · 2025: $2,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,753.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $504.46 | 2022-2025 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals Lp | $432.81 | 2022-2025 | Enhertu, Imfinzi, Calquence |
| Pfizer INC. | $367.22 | 2022-2025 | |
| Gilead Sciences, INC. | $360.76 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $341.60 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Bayer Healthcare Pharmaceuticals INC. | $295.20 | 2021-2025 | |
| Genzyme Corporation | $240.97 | 2022-2025 | |
| Janssen Biotech, INC. | $228.44 | 2021-2025 | Rybrevant, Erleada, Carvykti |
| Abbvie INC. | $221.99 | 2021-2025 | |
| Celgene Corporation | $208.14 | 2022-2025 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $161.58 | 2024-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $144.51 | 2022-2025 | Fruzaqla, Alunbrig |
| Glaxosmithkline, LLC. | $122.26 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Daiichi Sankyo INC. | $118.37 | 2021-2025 | Enhertu |
| Amgen INC. | $112.37 | 2021-2022 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $112.30 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Aveo Pharmaceuticals, INC. | $109.52 | 2022-2025 | Fotivda |
| Astellas Pharma US INC | $94.35 | 2022-2025 | Xtandi, Vyloy, Padcev |
| Seagen INC. | $93.05 | 2021-2023 | Tukysa, Adcetris |
| Lilly USA, LLC | $89.52 | 2023-2025 | Verzenio, Jaypirca |
| Pharmacyclics LLC, An Abbvie Company | $88.33 | 2021-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $86.23 | 2021-2025 | Opdualag, Opdivo |
| Sumitomo Pharma America, INC. | $80.29 | 2024-2025 | Orgovyx |
| Adc Therapeutics America, INC. | $79.06 | 2022-2025 | |
| Kite Pharma, INC. | $78.79 | 2024-2025 | Yescarta |
| Jazz Pharmaceuticals INC. | $75.91 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $68.11 | 2024-2025 | Monoferric |
| Taiho Oncology, INC. | $61.87 | 2024-2025 | |
| Genentech USA, INC. | $59.46 | 2023-2025 | Phesgo, Tecentriq, Polivy |
| Foundation Medicine, INC. | $58.52 | 2023 | |
| Emd Serono, INC. | $57.64 | 2022-2025 | Bavencio |
| Puma Biotechnology, INC. | $54.19 | 2021-2024 | |
| Array Biopharma INC | $52.38 | 2024-2025 | Braftovi, Mektovi, Xalkori |
| Kyowa Kirin, INC. | $50.06 | 2023-2025 | Poteligeo |
| Pharmaessentia USA Corporation | $49.59 | 2024-2025 | Besremi |
| Blueprint Medicines Corporation | $47.30 | 2023-2024 | Ayvakit |
| Eisai INC. | $43.39 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $42.12 | 2024-2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $40.60 | 2022-2025 | Qinlock, Romvimza |
| Geron Corporation | $39.83 | 2025 | Rytelo |
| Apellis Pharmaceuticals, INC. | $38.41 | 2023 | Empaveli |
| Rigel Pharmaceuticals, INC. | $37.14 | 2022 | |
| Legend Biotech USA INC. | $31.12 | 2025 | Carvykti |
| G1 Therapeutics, INC. | $31.05 | 2022 | |
| Genmab U.S., INC. | $29.83 | 2025 | Epkinly |
| Immunocore Limited | $27.10 | 2025 | Kimmtrak |
| Mirati Therapeutics, INC. | $26.41 | 2024 | Krazati |
| Tempus Ai, INC | $25.12 | 2024 | Xt Cdx |
| Servier Pharmaceuticals LLC | $22.10 | 2022 | |
| Tersera Therapeutics LLC | $21.70 | 2022 | |
| Karyopharm Therapeutics INC. | $20.07 | 2023 | Xpovio |
| Sun Pharmaceutical Industries INC. | $18.47 | 2025 | |
| Organon LLC | $16.72 | 2023 | Ontruzant |
| Dova Pharmaceuticals | $16.49 | 2021 | |
| Ge Healthcare | $14.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Blandford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.